Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Aug 25, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of different medications called Janus Kinase inhibitors (JAKi) for treating alopecia areata (AA), a condition that causes hair loss. The trial aims to gather real-world data on how well these medications work and who might benefit from them. Some of the JAK inhibitors being looked at include tofacitinib, baricitinib, and abrocitinib, among others. By understanding how these treatments perform outside of a controlled setting, the researchers hope to help doctors and patients make more informed decisions about treatment options.

To be eligible for this study, participants need to be between 2 and 18 years old and must have been diagnosed with alopecia areata according to specific guidelines. They should also have been receiving treatment with one of the JAK inhibitors for at least three months. However, patients who have had hair transplants or other types of hair loss due to different diseases will not be included. Those who participate can expect to share their health information and possibly receive valuable treatment insights that could help them or their loved ones in managing alopecia areata.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with alopecia areata between 2 to 18 years old
• • Patients diagnosed with alopecia areata according to AA guideline
• • AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months
• Exclusion Criteria:
• • Patients had previously received hair implants
• • Other alopecia
• • Other diseases may induce alopecia including psoriasis, lichen planus, et al.
• • Unable to estimate SALT score at baseline or at follow-up
• • Patients are participating in other clinical trials